Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Sep 30;59(1):51–60. doi: 10.2337/db09-0336

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2010 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 1. — A: Representative micrographs showing the in vivo transfection efficiency of Ad.LacZ in the nondiabetic sham-operated groups. Robust infection of the myocardium as assessed by β-galactosidase staining in the viable cardiac muscle surrounding the sites of gene transfer can be seen in the Ad.LacZ-transfected myocardium. B: Expression of VEGF as assessed by immunohistochemical staining. C: Expression of Ang-1 as assessed by immunohistochemical staining. The decrease in the expression of VEGF and Ang-1 is evident in the diabetic DS and DLZMI groups compared with the respective nondiabetic CS and CLZMI groups. Increase in the expression of VEGF and Ang-1 can be seen in the groups that received the combination gene therapy (CVAMI and DVAMI) compared with their respective (CLZMI and DLZMI) Ad.LacZ-treated groups. (−) represents representative micrographs showing the sections in which primary antibody was not added to verify the specificity of the staining protocol. CS, nondiabetic control sham; DS, diabetic sham; CLZMI, nondiabetic control animals that received Ad.LacZ injections; DLZMI, diabetic animals that received Ad.LacZ injections; CVAMI, nondiabetic control animals that received combination gene therapy; and DVAMI, diabetic animals that received combination gene therapy. (A high-quality color digital representation of this figure is available in the online issue.)